Get started
GSK PLC LS-,3125GSK PLC LS-,3125GSK PLC LS-,3125

GSK PLC LS-,3125

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GS71 chart


Full chart

Key facts today

GSK faces lawsuits over claims of misleading marketing for cold medicines with oral phenylephrine, which the U.S. FDA plans to ban from over-the-counter sales due to its lack of effectiveness.
Analyze the impactAnalyze the impact

GS71 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪67.10 B‬ EUR
Dividend yield (indicated)
4.45%
Price to earnings Ratio (TTM)
22.975
Basic EPS (TTM)
0.740 EUR
Net income (FY)
‪5.68 B‬ EUR
Revenue (FY)
‪34.98 B‬ EUR
Shares float
‪3.73 B‬
Beta (1Y)
0.69

Employees


Employees (FY)
‪70.21 K‬
Change (1Y)
+812 +1.17%
Revenue / Employee (1Y)
‪549.87 K‬ EUR
Net income / Employee (1Y)
‪89.35 K‬ EUR

About GSK PLC ORD GBP0.3125


Sector
Health Technology
CEO
Emma N. Walmsley
Headquarters
London
Website
gsk.com
ISIN
GB00BN7SWP63
FIGI
BBG000CTGY55
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GS71 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GS71 highest yielding bonds


G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
5.56%
Maturity date
Dec 18, 2045
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.40%
Maturity date
Apr 10, 2042
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.34%
Maturity date
Mar 9, 2039
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.24%
Maturity date
Mar 18, 2043
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.23%
Maturity date
May 15, 2038
G
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
4.99%
Maturity date
May 12, 2035
G
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.80%
Maturity date
Dec 19, 2033
G
72WI
GLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034
Yield to maturity
4.69%
Maturity date
Apr 15, 2034
G
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.55%
Maturity date
Jun 1, 2029
G
US377372AN7
GLAXOSMITHKLINE CAP.18/28
Yield to maturity
4.51%
Maturity date
May 15, 2028
G
XS217060184
GLAXOSM.CAP. MTN 20/28MTN
Yield to maturity
4.47%
Maturity date
Oct 12, 2028

Explore more bonds 

Sparks


Curated watchlists where GS71 is featured.

See all sparks 

Frequently Asked Questions


The current price of GS71 is 16.755 EUR — it has increased by 0.27% in the past 24 hours. Watch GSK PLC LS-,3125 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange GSK PLC LS-,3125 stocks are traded under the ticker GS71.
GS71 stock has risen by 2.18% compared to the previous week, the month change is a −3.57% fall, over the last year GSK PLC LS-,3125 has showed a 2.64% increase.
We've gathered analysts' opinions on GSK PLC LS-,3125 future price: according to them, GS71 price has a max estimate of 31.09 EUR and a min estimate of 16.92 EUR. Watch GS71 chart and read a more detailed GSK PLC LS-,3125 stock forecast: see what analysts think of GSK PLC LS-,3125 and suggest that you do with its stocks.
GS71 reached its all-time high on May 23, 2024 with the price of 21.570 EUR, and its all-time low was 14.620 EUR and was reached on Sep 26, 2022. View more price dynamics on GS71 chart.
See other stocks reaching their highest and lowest prices.
GS71 stock is 2.23% volatile and has beta coefficient of 0.69. Track GSK PLC LS-,3125 stock price on the chart and check out the list of the most volatile stocks — is GSK PLC LS-,3125 there?
Today GSK PLC LS-,3125 has the market capitalization of ‪67.19 B‬, it has decreased by −5.14% over the last week.
Yes, you can track GSK PLC LS-,3125 financials in yearly and quarterly reports right on TradingView.
GSK PLC LS-,3125 is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
GS71 earnings for the last quarter are 0.60 EUR per share, whereas the estimation was 0.53 EUR resulting in a 13.29% surprise. The estimated earnings for the next quarter are 0.25 EUR per share. See more details about GSK PLC LS-,3125 earnings.
GSK PLC LS-,3125 revenue for the last quarter amounts to ‪9.62 B‬ EUR, despite the estimated figure of ‪9.63 B‬ EUR. In the next quarter, revenue is expected to reach ‪9.32 B‬ EUR.
GS71 net income for the last quarter is ‪−69.66 M‬ EUR, while the quarter before that showed ‪1.38 B‬ EUR of net income which accounts for −105.03% change. Track more GSK PLC LS-,3125 financial stats to get the full picture.
GSK PLC LS-,3125 dividend yield was 4.00% in 2023, and payout ratio reached 47.69%. The year before the numbers were 4.26% and 16.49% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 8, 2024, the company has ‪70.21 K‬ employees. See our rating of the largest employees — is GSK PLC LS-,3125 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK PLC LS-,3125 EBITDA is ‪10.88 B‬ EUR, and current EBITDA margin is 30.62%. See more stats in GSK PLC LS-,3125 financial statements.
Like other stocks, GS71 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK PLC LS-,3125 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK PLC LS-,3125 technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK PLC LS-,3125 stock shows the strong sell signal. See more of GSK PLC LS-,3125 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.